ABSTRACT
Ataxia-telangiectasia (A-T) is a rare genetic disease caused by mutations in the gene encoding the ATM (ataxia-telangiectasia mutated) protein. Although neuronal degeneration in the cerebellum remains the most prominent sign in A-T pathology, neuroimaging studies reveal myelin abnormalities as early comorbidities. We hypothesize that these myelin defects are the direct consequence of ATM deficiencies in the oligodendrocytes (OL) lineage. We examined samples from ten A-T brains in which the ATM mutations had been mapped by targeted genomic sequencing and from Atm-/- mice. In healthy human cerebellum, we confirmed the presence of ATM in white matter OLs. In A-T, a significant reduction in OL density was found along with a massive astrogliosis. This white matter pathology was recapitulated in Atm-/- mice in an age- and gene dose-dependent fashion. Activated ATM was found expressed both in the nucleus and cytoplasm of OL progenitor cells (OPC) and myelinating mature OL. Its presence in the OL lineage is associated with novel OL-specific functions of the ATM protein affecting all stages of the OL life cycle. Blockage of ATM activity with KU-60019 or inducing DNA damage induced with etoposide altered the cell cycle in self-renewing OPC and triggered ectopic cell cycle re-entry in mature OL in vitro. Further, the differentiation program of OPC is highly sensitive to DNA damage either induced directly or by blocking DNA repair. As much of the impact of ATM deficiency in OL is independent of neuronal loss, our findings have important implications for the complex neurological symptoms of human A-T.
HIGHLIGHTS
Oligodendrocytes are highly vulnerable to DNA double strand breaks
ATM regulates cell cycle control and differentiation of oligodendrocytes
Myelin-pathology in Ataxia Telangiectasia is likely the cell-autonomous consequence of ATM deficiency in oligodendrocytes
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The present work was generously supported by Health and Medical Research Fund (HMRF06173836 and HMRF04151436) of the Food and Health Bureau, Hong Kong Special Administrative Region, as well as National Institute of Neurological Disorders and Stroke (NINDS) R01NS071022-01. We acknowledge the kind support from the staff at NeuroBioBank of National Institutes of Health (NIH). All frozen human tissue in this study was obtained from the NIH NeuroBioBank at the University of Maryland, Baltimore, MD, and the PPFE tissues from Neuropathology Core, University of Pittsburgh Alzheimer's Disease Research Center, United States. Dr Kofler and Alzheimer's Disease Research Center at the University of Pittsburgh are supported by NIA P30 AG066468 and NIA P50 AG005133. Dr Jiang and the TEM work are supported by AoE/M-05/12.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All experiments on post-mortem human brain tissues were approved by the Committee of Research Practices at The Hong Kong University of Science and Technology (HKUST) as well as Human Subjects Ethics Application Review board at The Hong Kong Polytechnic University (PolyU) All experimnets on animal models were approved by the Animal Ethics Committee, of the Committee on Research Practices of HKUST and Animal Subjects Ethics Sub-Committee of PolyU. All procedures were also conducted with a license from the Department of Health, Government of Hong Kong.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This version is based on reviewers' recommendation to split the original manuscript (doi.org/10.1101/2021.01.22.20245217 deposited on January 26, 2021) into two medRxiv submissions. This first submission (deposited on 9th November, 2023) focuses on the ATM deficiency in oligodendrocytes, and the second medRxiv submission (to be deposited in due course) will focus on the effect of specific ATM mutation on oligodendrocyte differentiation.
